SuperworthLantheus LNTH
- Market cap
- $6.5B
- PE
- 24.2×
- 10y median 24.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 4.2×
- EV/EBIT
- 20.6×
- Revenue, 12 months
- $1.6B
- +2% on a year ago
- Net margin
- 17.7%
- Free cash flow yield
- 6.0%
Lantheus trades at 24.2× trailing earnings, near its ten-year median. Revenue was $1.6B over the last twelve months, up 2% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $319.9M+34% | $354M+35% | $370M+23% | $394.1M+23% | $378.7M+18% | $391.1M+11% | $372.8M+1% | $378M−4% | $384M+1% | $406.8M+4% | $377.3M+1% | $388.2M+3% | |
| Cost of revenue | $120M+31% | $124.1M+29% | $128.1M−43% | $138.3M+16% | $136.6M+14% | $142.6M+15% | $135.1M+5% | $137M−1% | $161.6M+18% | $165.9M+16% | $146.4M+8% | $146.3M+7% |
| Gross profit | $200M+36% | $229.9M+38% | $241.8M+214% | $255.8M+26% | $242.1M+21% | $248.5M+8% | $237.7M−2% | $241M−6% | $222.4M−8% | $240.9M−3% | $230.9M−3% | $241.9M+0% |
| R&D | $14.4M+15% | $16.8M−94% | $48M+57% | $60.6M+281% | $24.1M+67% | $35.3M+110% | $36.3M−24% | $45.5M−25% | $48M+99% | $47.5M+34% | $39.4M+8% | $38.2M−16% |
| SG&A | $73.1M+49% | $75.6M+13% | $93.4M+67% | $92.4M+48% | $84.2M+15% | $101.5M+34% | $99.3M+6% | $107.6M+16% | $130.7M+55% | $116.2M+15% | $110.2M+11% | $103.4M−4% |
| $112.4M+31% | $137.5M | $106.6M | $102.7M−17% | $133.7M+19% | $113.9M−17% | $102.1M−4% | $88M−14% | $43.6M−67% | $77.2M−32% | $81.3M−20% | $100.2M+14% | |
| Interest expense | $5.1M+211% | $5M+95% | $4.9M−3% | $4.9M−1% | $4.9M−3% | $5M+0% | $4.8M−1% | $4.9M+1% | $5M+1% | $5.1M+1% | $4.9M+1% | $4.9M+0% |
| Pre-tax income | $160M+93% | $138.4M | $171.3M | $84.4M−32% | $176.1M+10% | −$783K | $96.5M−44% | $104.5M+24% | $42.4M−76% | $70.4M | $156.4M+62% | $93.8M−10% |
| $28M+29% | $35M | $40.2M | $22.3M−25% | $45M+61% | $11M−69% | $23.6M−41% | $25.8M+16% | $14.6M−68% | $16.3M+48% | $38M+61% | $18.8M−27% | |
| Net income | $132M+116% | $103.4M | $131.1M | $62.1M−34% | $131.1M−1% | −$11.8M | $72.9M−44% | $78.8M+27% | $27.8M−79% | $54.1M | $118.4M+62% | $75M−5% |
| $1.88+119% | $1.47 | $1.87 | $0.88−34% | $1.79−5% | −$0.17 | $1.02−46% | $1.12+27% | $0.41−77% | $0.81 | $1.80+77% | $1.11−1% | |
| 70M−1% | 70.2M+2% | 70.1M+4% | 70.6M−1% | 73.1M+4% | 69.2M−1% | 71.5M+2% | 70.3M−0% | 67.7M−7% | 66.7M−4% | 65.8M−8% | 67.5M−4% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
R&D: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
SG&A: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Income tax: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them. 21 periods, Q2 FY14 to Q3 FY19: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q1 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 8 periods, Q4 FY14 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LNTHLantheus | $6.5B | 24.2× | 24.0× | n/m | 4.2× | +2% | 17.7% |
| BLLNBillionToOne | $5.1B | 166× | 151× | n/m | 12.8× | +90% | 9.5% |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | n/m | 9.1× | +85% | 10.6% |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | n/m | 3.8× | +1% | 8.6% |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | n/m | 6.9× | +17% | 20.4% |
| CDNACareDx | $3.6B | 33.4× | 19.1× | n/m | 7.8× | +34% | 24.2% |
| RVTYRevvity | $17.7B | 75.6× | 34.8× | n/m | 6.1× | +4% | 8.2% |
| MEDPMedpace | $18.7B | 39.2× | 34.5× | n/m | 6.7× | +25% | 17.7% |
| LHLabcorp | $26.7B | 27.2× | 19.4× | 17.4× | 1.9× | +6% | 7.0% |
| DGXQuest Diagnostics | $26.7B | 25.7× | 19.3× | n/m | 2.3× | +9% | 9.2% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| Peer median | $13.8B | 38.4× | 34.7× | 25.6× | 6.8× | +13% | 10.1% |
Investors who own it
Investors we follow who held Lantheus at the end of Jun 30, 2026, from their 13F filings.
- Reinhart PartnersReinhart Partners4.1% of portfolioadded
More on Lantheus
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 20Diagnostics and research stocks with the lowest PE ratio
- #2of 28Diagnostics and research stocks with the highest free cash flow yield
- #4of 25Diagnostics and research stocks with the lowest EV/EBIT
- #7of 39Diagnostics and research stocks with the highest profit margins
- #4of 15Diagnostics and research stocks cheapest against their own PE history
- #10of 17Diagnostics and research stocks with the fastest earnings growth
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .